¹⁸F-PSMA-1007 PET in Biochemical Recurrent Prostate Cancer: An Updated Meta-Analysis

Table 3

Main findings of the included studies about ¹⁸F-PSMA-1007 PET/CT or PET/MRI in patients with biochemical recurrence of prostate cancer.

Authors	Overall DR	DR in patients with PSA <0.5 ng/mL	DR in patients with PSA ≥0.5 ng/mL	DR in patients with PSA between 0.5 and <1 ng/mL	DR in patients with PSA between 1 and <2 ng/mL	DR in patients with PSA ≥2 ng/mL	Mean PSA in patients with positive PET/CT (ng/mL)	Mean PSA in patients with negative PET/CT (ng/mL)	Change of management using ^18F-PSMA-1007 PET/CT or PET/MRI
Ahmadi Bidakhvidi et al. [22]	140/175 (80%)	NR	NR	NR	NR	NR	NR	NR	NR
Dietlein et al. [23]	16/23 (69.6%)	NR	NR	NR	NR	NR	NR	NR	NR
Giesel et al. [24]	9/12 (75%)	3/5 (60%)	6/7 (86%)	1/2 (50%)	1/1 (100%)	4/4 (100%)	2.38 ± 2.3	0.38 ± 0.18	8/12 (67%)
Giesel et al. [25]	204/251 (81.3%)	40/65 (61.5%)	164/186 (88.2%)	35/47 (74.5%)	50/55 (90.9%)	79/84 (94%)	6.8 ± 22.4	0.95 ± 1.56	NR
Liu et al. [26]	20/22 (90.9%)	0/2 (0%)	20/20 (100%)	100%	100%	100%	NR	NR	14/22 (63.6%)
Morawitz et al. [27]	20/23 (87%)	NR	NR	NR	NR	NR	NR	NR	NR
Rahbar et al. [28]	26/28 (93%)	NR	NR	NR	NR	NR	NR	NR	NR
Rahbar et al. [29]	95/100 (95%)	18/21 (85.7%)	77/79 (97.5%)	16/18 (88.9%)	22/22 (100%)	39/39 (100%)	NR	NR	NR
Rauscher et al. [30]	82/102 (80.4%)	NR	NR	NR	NR	NR	NR	NR	NR
Sachpekidis et al. [31]	8/17 (47.1%)	1/5 (20%)	7/12 (58.3%)	1/5 (20%)	4/4 (100%)	2/3 (66.7%)	1.8 ± 1.5	0.8 ± 0.9	NR
Sprute et al. [32]	NR	NR	NR	NR	NR	NR	NR	NR	NR
Watabe et al. [33]	26/28 (92.9%)	66.7%	NR	85.7%	100%	100%	NR	NR	22/28 (78.6%)
Witkowska-Patena et al. [34]	24/40 (60%)	NR	NR	NR	NR	NR	NR	NR	NR
Witkowska-Patena et al. [35]	24/40 (60%)	7/18 (38.9%)	17/22 (77.3%)	6/11 (54.5%)	10/10 (100%)	1/1 (100%)	1.01 ± 0.64	0.37 ± 0.28	NR
Wondergem et al. [36]	NR	NR	NR	NR	NR	NR	NR	NR	NR

 = not included in the meta-analysis for possible patient data overlap; # = not included in the meta-analysis for insufficient data to calculate the per scan-based detection rate; CT = computed tomography; DR = detection rate on a per scan-based analysis; MRI = magnetic resonance imaging; NR = not reported; PET = positron emission tomography; PSA = prostate-specific antigen.